ESMO 2019 | SCLC hyperprogression with nivolumab

Martin Reck

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses an analysis of tumor hyperprogression (HP) with nivolumab in small- cell lung cancer (SCLC) randomized, placebo-controlled trials. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics